Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28283506 | 0.85 | TSHR (0.46) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL28419157 | 0.82 | TSHR (0.44) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL21944189 | 0.78 | TSHR (0.53) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL3097256 | 0.76 | KMT2A (0.60) | TSHRCES1L3MBTL1TDP1NPC1 | |
| SCHEMBL5593472 | 0.76 | TSHR (0.47) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL21676974 | 0.75 | MEN1 (0.47) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL934793 | 0.75 | TSHR (0.50) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL5140966 | 0.75 | POLB (0.51) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| SCHEMBL106992 | 0.74 | TSHR (0.53) | TSHRCES2CES1AKR1B1L3MBTL1 | |
| Ether SCHEMBL9819680 | 0.74 | CES1 (0.52) | TSHRCES2CES1AKR1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | TSHR 4273/4885CES2 4870/4885CES1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.